The Cetrelimab–Erdafitinib Combination Shows Promise in Advanced Bladder and Urinary Tract Cancer

Among patients with tumor FGFR alterations and previously untreated locally advanced or metastatic urothelial (bladder and urinary tract) cancer who are ineligible for cisplatin, the pan-FGFR inhibitor erdafitinib plus the anti-PD-1 agent cetrelimab was reported to double the response rate at the ESMO 2021 Virtual Congress.
Erdafitinib, for patients with FGFR3 or FGFR2 genetic alterations who had previously received platinum-based chemotherapy and had locally advanced or metastatic urothelial cancer, received, on April 12, 2019, FDA approval (see the related approval). We also know that immunotherapies are effective in bladder cancer. This led to the idea of combining two new classes of cancer drugs.
Views on the NORSE Study
Speaking at the ESMO Congress 2021, researcher Thomas Powles (Barts Cancer Institute, London, United Kingdom) highlighted the "substantial unmet need" for treatment options for people with advanced urothelial cancer who are ineligible for cisplatin.
He explained that there was a "strong rationale" for combining erdafitinib and cetrelimab because "neoantigen release by erdafitinib can prime the tumor microenvironment for a response to immune checkpoint blockade," resulting in synergy.
Powles presented an interim analysis of the NORSE study in patients positive for FGFR mutations or fusions. This phase 2 portion involved 53 patients diagnosed with locally advanced or metastatic urothelial cancer.
Participants were randomly assigned to one of two arms to receive either erdafitinib 8 mg daily together with intravenous cetrelimab at a dose of 240 mg every 2 weeks for four cycles and then 480 mg every 4 weeks, or erdafitinib alone at the same dose.
The primary endpoint the study aimed to measure was overall response rate.
Results
- Treatment responses occurred in 68% of the 19 evaluable patients in the cetrelimab plus erdafitinib group and 33% of the 18 evaluable patients in the erdafitinib-alone group. Complete response rates were 21% and 6%, respectively.
- Median duration of response was 6.9 months in patients receiving cetrelimab plus erdafitinib and was not reached in those given erdafitinib alone. Responses were ongoing at the time of analysis in 10 of the 13 responders in the combination arm and five of the six responders in the monotherapy arm.
Powles said that the combination’s safety profile was "generally similar to that of erdafitinib alone," with Grade 3 treatment-emergent adverse events (TEAEs) occurring in 50% of patients treated with the combination and 38% of those given erdafitinib alone. The most common adverse events of this severity in the combination arm, affecting 12.5% of patients, were stomatitis and elevated lipase, while anemia and general physical deterioration were the most common in the monotherapy arm, again each occurring at a rate of 12.5%.
In 29% of the combination group, adverse events led to the discontinuation of cetrelimab, erdafitinib or both, while the discontinuation rate in the erdafitinib group was 8%. One death in the combination treatment arm was attributed to respiratory failure and was considered related to cetrelimab.
Comment
These data suggest that, in patients with FGFR alterations and advanced urothelial carcinoma, erdafitinib plus cetrelimab has a synergistic effect. Enrollment in the NORSE study is ongoing and is supported by these data.
Sources
Was this article helpful?
Your feedback helps us improve our content.





Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.